These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38139461)

  • 21. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-viral engineering of NK cells.
    Hinnekens C; De Smedt SC; Fraire JC; Braeckmans K
    Biotechnol Adv; 2023 Nov; 68():108212. PubMed ID: 37454745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How can Cytokine-induced killer cells overcome CAR-T cell limits.
    Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
    Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
    Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
    Front Immunol; 2021; 12():717850. PubMed ID: 34447383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Adoptive Cellular Therapy With Non-T-Cell Immune Effectors the Future?
    Ali AK; Tarannum M; Romee R
    Cancer J; 2021 Mar-Apr 01; 27(2):168-175. PubMed ID: 33750077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
    Li Y; Rezvani K; Rafei H
    Immunol Rev; 2023 Nov; 320(1):217-235. PubMed ID: 37548050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineered NK Cells Against Cancer and Their Potential Applications Beyond.
    Karvouni M; Vidal-Manrique M; Lundqvist A; Alici E
    Front Immunol; 2022; 13():825979. PubMed ID: 35242135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
    Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
    Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response.
    Cienfuegos-Jimenez O; Vazquez-Garza E; Rojas-Martinez A
    Curr Gene Ther; 2022; 22(4):303-318. PubMed ID: 34923939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

  • 32. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
    Kilgour MK; Bastin DJ; Lee SH; Ardolino M; McComb S; Visram A
    Front Immunol; 2023; 14():1166038. PubMed ID: 37205115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T Cell Therapy: From the Shop to Cancer Therapy.
    Uscanga-Palomeque AC; Chávez-Escamilla AK; Alvizo-Báez CA; Saavedra-Alonso S; Terrazas-Armendáriz LD; Tamez-Guerra RS; Rodríguez-Padilla C; Alcocer-González JM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing natural killer cells to develop next-generation cellular immunotherapy.
    Liu S; Nguyen K; Park D; Wong N; Wang A; Zhou Y
    Chronic Dis Transl Med; 2022 Dec; 8(4):245-255. PubMed ID: 36420177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
    Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
    J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.